CISON PR Newswire – RLF-100™ therapy associated with a 9-fold increased probability of survival and recovery from respiratory failure in an open-label, prospective study– Top-line data from randomized, placebo-controlled Phase 2b/3 trial expected this quarter GENEVA and RADNOR, Pa., Oct. 13, 2020 /PRNewswire/ — RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) and NeuroRx, Inc., today announced topline results from 45 […]
By Lia Eustachewich, NY Post The race is on to find a treatment that works to quash the coronavirus — as the deadly disease continues to spread across the globe. Here’s a list of the most promising treatments and potential vaccines for SARS-CoV-2, the virus that causes COVID-19. Remdesivir The experimental antiviral drug, made by Gilead Sciences, was […]
CISON PR Newswire Emergency Use Authorization request targets the same population as is currently permitted under FDA Expanded Access Protocol RADNOR, Pa., Sept. 23, 2020 /PRNewswire/ — NeuroRx, Inc. has submitted a request for an Emergency Use Authorization (EUA) with the US FDA for the use of RLF-100™ aviptadil in patients who are receiving intensive care […]
CISION PR Newswire – Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites – Aviptadil is being developed as the first COVID therapeutic to block replication of the […]
By Tova Cohen; Reuters TEL AVIV (Reuters) – Critically ill COVID-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United States, two drug companies said on Sunday. Geneva-based Relief Therapeutics Holdings AG RFLB.S has a patent for RLF-100, or aviptadil, a synthetic form of […]
With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine.
University of Miami Health System
Thompson Reuters TEL AVIV, March 29 (Reuters) – The U.S. Food & Drug Administration has authorised the start of a mid-stage trial by U.S.-Israeli NeuroRx and Relief Therapeutics for the use of Aviptadil to treat Acute Respiratory Distress in coronavirus patients. The companies said on Sunday they are recruiting study sites and pharmacies to begin […]